Drug Trial Radar · NCT00112918
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
Last checked: Nov 19, 2026Latest source record: Aug 27, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,451
Actual
Start
Dec 2004
Primary completion
Jun 2010
Study completion Jun 2012
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 3, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab (Bv) may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer in adjuvant setting. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens with or without bevacizumab to compare how well they work in treating patients who have undergone surgery for high risk stage II or stage III colon cancer.
Conditions
- Colorectal Cancer
Interventions
BevacizumabBiological
Administered as an intravenous infusion over 30 - 90 minutes.
CapecitabineDrug
Film-coated tablets
5-Fluorouracil (5-FU)Drug
Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
Leucovorin calciumDrug
Administered as a 200 mg/m\^2 infusion over 2 hours.
OxaliplatinDrug
Administered as an intravenous infusion over 2 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free Survival in Stage III Cancer Patients - Time to EventTime frame: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
- Disease-free Survival in Stage III Cancer Patients - Number of EventsTime frame: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.